Zacks Investment Research upgraded shares of Takeda Pharmaceutical (NYSE:TAK) from a hold rating to a buy rating in a research note issued to investors on Wednesday, Zacks.com reports. They currently have $20.00 target price on the stock.
According to Zacks, “Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda’s core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan. “
Several other brokerages have also recently commented on TAK. Goldman Sachs Group reissued a buy rating on shares of LVMH Moet Hennessy Louis Vuitton in a report on Tuesday, March 19th. ValuEngine raised Vermillion from a hold rating to a buy rating in a report on Wednesday, May 15th.
Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Tuesday, May 14th. The company reported $0.13 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 12.18% and a net margin of 10.60%. The firm had revenue of $3.51 billion for the quarter. On average, equities analysts predict that Takeda Pharmaceutical will post 0.44 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Shelton Capital Management bought a new position in shares of Takeda Pharmaceutical in the first quarter valued at $46,000. Hudock Capital Group LLC bought a new position in shares of Takeda Pharmaceutical in the first quarter valued at $26,000. Global Retirement Partners LLC increased its holdings in shares of Takeda Pharmaceutical by 63.3% in the first quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock valued at $70,000 after buying an additional 1,326 shares in the last quarter. Shine Investment Advisory Services Inc. bought a new position in shares of Takeda Pharmaceutical in the first quarter valued at $28,000. Finally, Contravisory Investment Management Inc. bought a new position in shares of Takeda Pharmaceutical in the first quarter valued at $28,000. 11.44% of the stock is currently owned by institutional investors.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Further Reading: What are the qualifications of a portfolio manager?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.